Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Work In Process (2021 - 2024)

Protagonist Therapeutics (PTGX) has disclosed Work In Process for 4 consecutive years, with $165.0 million as the latest value for Q4 2024.

  • Quarterly Work In Process rose 1550.0% to $165.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $165.0 million through Dec 2024, up 1550.0% year-over-year, with the annual reading at $165.0 million for FY2024, 1550.0% up from the prior year.
  • Work In Process hit $165.0 million in Q4 2024 for Protagonist Therapeutics, up from $43000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $300.0 million in Q1 2024 to a low of $10000.0 in Q4 2022.
  • Historically, Work In Process has averaged $68.1 million across 4 years, with a median of $1.6 million in 2021.
  • Biggest five-year swings in Work In Process: crashed 99.36% in 2022 and later surged 99900.0% in 2023.
  • Year by year, Work In Process stood at $1.6 million in 2021, then plummeted by 99.36% to $10000.0 in 2022, then soared by 99900.0% to $10.0 million in 2023, then surged by 1550.0% to $165.0 million in 2024.
  • Business Quant data shows Work In Process for PTGX at $165.0 million in Q4 2024, $43000.0 in Q2 2024, and $300.0 million in Q1 2024.